

The Dog Model of Left Ventricular Remodeling After Myocardial Infarction

BODH I. JUGDUTT, MD

Edmonton, Alberta, Canada

ABSTRACT

Background: For over a century, the dog model has been used widely in research studying cardiovascular physiology pertinent to humans. It has been specially applied, over the past 2 decades, in research on the pathophysiology and treatment of left ventricular (LV) remodeling and heart failure.

Methods and Results: Because progressive LV remodeling and the march to heart failure are major problems facing myocardial infarction (MI) survivors, the dog model of acute MI was modified for the study of LV structural remodeling and dysfunction during post-MI healing (especially anterior MI). The dog model of post-MI LV remodeling, as the other models, has contributed to our understanding of the pathophysiology of LV remodeling and underlying mechanisms, and to the development of improved therapeutic strategies. Recent increase in costs and public concern over their use in research should be considered when using this model

Conclusions: This is an important model for studying strategies to prevent severe LV remodeling in humans.

Key Words: Healing, reperfusion, echocardiography, collagen.

Introduction

Models for studying left ventricular (LV) remodeling after myocardial infarction (MI) and heart failure range from those involving large animals (eg, the dog, pig, sheep) to those involving small animals (eg, the rabbit, rat, mouse). The models can be classified into those in which the initial insult is regional (eg, MI, reperfused in-

faction, direct current (DC) shock injury), global (eg, pressure overload, volume overload, tachycardia/ventricular pacing, microembolization), or genetic. The processes of LV remodeling and healing after MI are dynamic and time-dependent, and progress in parallel.^{1,2} Thus, remodeling spans the phases of infarction, healing before and after collagen deposition, and subsequent scar formation.² Several points need to be considered when deciding which model to use. Caution should clearly be exercised in extrapolating results from animals, even large animals, to humans. No ideal large animal model exists for studying cardiac remodeling in humans. Major differences among large animal models should be recognized, such as differences in coronary circulation, infarct location, healing, neurohumoral pathways, and receptor populations. The importance of the extracellular matrix³ and the potential differences in its contribution to the remodeling process in various models should also be considered. Finally, whether we can prevent, reverse, or correct cardiac remodeling^{2,6} more easily in one model versus another should be considered. This review focuses on the canine post-MI model of LV remodeling.

From the Division of Cardiology, Department of Medicine, University of Alberta, and the University of Alberta Hospital, Edmonton, Alberta, Canada.

Supported in part by a grant from the Canadian Institutes of Health Research, Ottawa, Ontario, Canada.

Presented in part at the Remodeling and Progression of Heart Failure, Post-conference Satellite Meeting of the XVII World Congress of the International Society for Heart research, Minneapolis, Minnesota, July 12-14, 2001.

Reprint requests: Bodh I. Jugdutt, MD, 2C2.43 Walter MacKenzie Health Sciences Centre, Division of Cardiology, Department of Medicine, Edmonton, Alberta, Canada T6G 2R7.

Copyright 2002, Elsevier Science (USA). All rights reserved.

1071-9164/02/0806-0046\$35.00/0

doi:10.1054/jcaf.2002.129274

Post-infarct Remodeling in the Dog

Both anesthetized^{7,8} and conscious^{7,9-11} dog models of MI after coronary artery ligation have been adapted for studies of chronic LV remodeling during post-MI healing.¹¹⁻¹⁶ The chronically instrumented dog model has been validated for postmortem quantitation of infarct scar size relative to the risk region⁷⁻⁹ and for the mapping of regional myocardial blood flow,^{9,10} regional function by two-dimensional echocardiography (2D echo),^{11,17} regional collagen content,¹² and topography and regional bulging in transverse and long-axis planes.¹³⁻¹⁵ In the dog model healing is completed over a period of about 6 weeks.¹² The exact duration of healing is dependent on infarct size and transmural extent.^{2,12} Serial noninvasive imaging with 2D echo permits in vivo quantitation of changes in regional and global shape, structure, and function with relative ease.^{13-15,17} It is therefore especially suitable for studies of post-MI remodeling. Serial hemodynamic parameters (eg, atrial and arterial pressures) are recorded via indwelling catheters.⁹⁻¹⁵ Sonomicrometer implants allow continuous serial measurements of regional wall thickness and cavity dimensions.¹⁶ Serial electrocardiograms can also be monitored continuously.⁹⁻¹⁵

The collateral-rich dog model of predominantly subendocardial infarction can be modified to consistently produce transmural anteroapical infarcts and aneurysms by separately ligating visible collateral feeders below the coronary ligation.^{14,15} Ligation of the mid-left anterior descending coronary artery, together with ligation of the collateral inflow, results in transmural infarcts that are still small ($\leq 20\%$ LV), therefore long-term mortality is fairly low (10%-15%). In addition, because the infarcts are transmural, significant remodeling with aneurysmal bulging occurs.^{14,15} Higher coronary occlusions result in large infarcts and lower survival rates beyond one week (mortality $> 15\%$). Thus, the modified dog model is useful for chronic studies of changes in structure, geometry, and function during healing in survivors of acute MI.²

Methodological and Other Practical Details

We prefer 18- to 21-kg mongrel dogs⁹⁻¹⁵ for chronic studies. Instrumentation is done under general anesthesia (barbiturate or isoflurane), using a limited left lateral thoracotomy and room air ventilation in a sterile surgical suite. Indwelling catheters (jugular vein, carotid artery, and left atrium) are inserted and exteriorized behind the neck. We use mid-left anterior descending coronary artery ligation because anterior MI results in more LV

remodeling and dysfunction. For some studies of inferior MI, we use mid-left circumflex coronary artery ligation. The 48-hour mortality with both types of occlusion is $\leq 15\%$. In the last 100 animals with MI studied in our laboratory, the mortality was actually $< 10\%$ and morbidity $< 10\%$. Reperfusion after 2 to 3 hours^{16,18,19} causes higher 48-hour mortality ($\leq 25\%$) related to arrhythmias. We use collateral obliteration with ligation of visible epicardial vessels feeding the risk zone to increase transmural extent.^{14,15} This carries a higher 48-hour mortality ($\leq 35\%$), but the degree of anteroapical remodeling is dramatic,^{14,15} resembling the sheep model.^{20,21} We use epicardial beads sutured in the plane of the mid-occluded bed for consistent 2D echo imaging.¹³⁻¹⁵ We also implant sonomicrometer or sonometric crystals to study thickening¹⁷ and shape. In some animals, we implant a snare device or balloon occluder for late occlusion in the conscious state.⁹⁻¹¹ We have begun monitoring our animals postoperatively over the first 24 to 48 hours and administering analgesics for pain control. Animals usually recover from surgery within 48 hours. Subsequently, regular catheter care is carried out to ensure catheter patency. We use telemetry implants in some animals, thus avoiding the need for catheter care.

We usually record serial hemodynamics (aortic and left atrial pressures, EKG) and 2D echo at baseline before occlusion and serially postocclusion at 4 hours, 3 days, and weekly over 6 weeks or more. Serial functional and topographical parameters on 2D echo include LV volumes (Simpson's Rule) and LV mass (myocardial volume $\times 1.05$), LV function (LV asynergy, ejection fraction, shape index, and globularity index), and LV regional topography (expansion index, thinning ratio, apical bulge, and aneurysm).^{17,18} We use radioactive microspheres to measure regional myocardial flow.^{9-11,15,22} Animals are usually euthanized at 6 weeks, and hearts are used for topographic and other studies. Hearts are arrested in diastole with intravenous potassium chloride (KCl) and formalin-fixed in distension to preserve diastolic proportions.^{9,10} The risk region is determined using postmortem coronary arteriograms and radiographs of the whole heart and transverse sections.^{9,10} Infarct or scar size is measured by computerized planimetry.¹³⁻¹⁵ Long-axis LV topographic parameters from whole heart radiographs include shape index and extent of apical bulge.^{13,23,24} We perform histopathology and measure regional hydroxyproline (mg/g dry tissue).^{12,25} Analyses are done in a blinded fashion on coded data. Pertinent special procedures include scanning microscopy on fresh samples for assessment of matrix integrity¹⁴ and measurement of the LV rupture threshold.^{26,27} Because dogs, like humans, derive a substantial amount of angiotensin II from chymase,²⁸ this model is useful for translational research and evaluation of effects of therapies such as angiotensin II receptor antagonists (ARBs).

Discussion

The canine model of post-MI LV remodeling has contributed to knowledge of the progressive pathophysiologic changes associated with the MI healing process.² The ease with which 2D echo can be performed on awake dogs has provided insights into the in vivo shape, structural, and functional changes after MI. However, the post-MI dog model has not been as effective for studying remodeling during moderate-to-severe heart failure as the tachycardia-induced heart failure model,⁴ the micro-embolization heart failure model,^{29,30} or after a large MI as in the rat.²⁵ This is because post-MI canine survivors tend to have infarcts averaging 20% LV at 2 days and 10% at 6 weeks. Moreover, even animals with the relatively small infarcts in this model³¹ or the discrete DC-shock necrosis model³² show evidence of significant neurohumoral activation. The recent escalation in the cost of dogs for research has become a major concern. As the dog is considered "man's best friend," attention to the humane care of the animals is an important aspect of their use in research on prevention of cardiac remodeling.

References

1. Pfeffer MA, Braunwald E: Ventricular remodeling after myocardial infarction. *Circulation* 1990;81:1161-1172
2. Jugdutt BI: Prevention of ventricular remodeling post myocardial infarction: timing and duration of therapy. *Can J Cardiol* 1993;9:103-114
3. Weber KT: Cardiac interstitium in health and disease: the fibrillar collagen matrix. *J Am Coll Cardiol* 1989;13:1637-1652
4. Armstrong PW, Stopps TP, Ford SE, De Bold AJ: Rapid ventricular pacing in the dog: pathophysiologic studies of heart failure. *Circulation* 1986;74:1075-1084
5. Weber KT, Pick R, Silver MA, Moe GW, Janicki JS, Zucker LH, Armstrong PW: Fibrillar collagen and remodeling of dilated canine left ventricle. *Circulation* 1990;82:1387-1401
6. Jugdutt BI: Prevention of ventricular remodeling after myocardial infarction and in congestive heart failure. *Heart Failure Rev* 1996;1:115-129
7. Reimer KA, Jennings RB, Cobb FR, Murdock RH, Greenfield JC Jr, Becker LC, Bulkley BH, Hutchins GM, Schwartz RP Jr, Baily KR: Animal models for protecting ischemic myocardium: results of the NHLBI Cooperative Study. Comparison of conscious and unconscious dog models. *Circ Res* 1985;56:651-665
8. Lowe JE, Reimer KA, Jennings RB: Experimental infarct size as a function of the amount of myocardium at risk. *Am J Pathol* 1978;90:363-376
9. Jugdutt BI, Hutchins GM, Bulkley BH, Becker LC: Myocardial infarction in the conscious dog: three-dimensional mapping of infarct, collateral flow and region at risk. *Circulation* 1979;60:1141-1150
10. Jugdutt BI, Becker LC, Hutchins GM: Early changes in collateral blood flow after coronary occlusion and relation to infarction in the conscious dog. *Am J Physiol* 1979;237:H371-H380
11. Lieberman AN, Weiss JL, Jugdutt BI, Becker LC, Bulkley BH, Garrison JB, Hutchins GM, Kallman CA, Weisfeldt ML: 2D-Echo and infarct size: relationship of regional wall motion and thickening to the extent of myocardial infarction in the dog. *Circulation* 1981;63:739-746
12. Jugdutt BI, Amy RW: Healing after myocardial infarction in the dog: changes in infarct hydroxyproline and topography. *J Am Coll Cardiol* 1986;7:91-102
13. Jugdutt BI, Khan MI, Jugdutt SJ, Blinston GE: Effect of enalapril on ventricular remodeling and function during healing after anterior myocardial infarction in the dog. *Circulation* 1995;91:802-812
14. Jugdutt BI, Tang SB, Khan MI, Basualdo CA: Functional impact on remodeling during healing after non-Q-wave versus Q-wave anterior myocardial infarction in the dog. *J Am Coll Cardiol* 1992;20:722-731
15. Jugdutt BI, Khan MI: Impact of increased infarct transmural extent on remodeling and function during healing after anterior myocardial infarction in the dog. *Can J Physiol Pharmacol* 1992;70:949-958
16. Kambayashi M, Miura T, Oh BH, Murata K, Rockman HA, Parra G, Ross J Jr: Myocardial cell hypertrophy after myocardial infarction with reperfusion in dogs. *Circulation* 1992;86:1935-1944
17. Jugdutt BI, Manyari DE, Humen DP: Detection of viability of dysfunctional myocardium in coronary heart disease. II. Echocardiography. *Heart Failure Reviews* 1998;2:207-233
18. Jugdutt BI: Effect of reperfusion on ventricular mass, topography and function during healing of anterior infarction. *Am J Physiol* 1997;272:H1205-H1211
19. Becker LC, Jeremy RW, Schaper J, Schaper W: Ultrastructural assessment of myocardial necrosis occurring during ischemia and 3-h reperfusion in the dog. *Am J Physiol* 1999;277:H243-H252
20. Markovitz LJ, Savage EB, Ratcliffe MB, Bavaria JE, Kreiner G, Iozzo RV, Hargrove WC III, Bogen DK, Edmunds LH Jr: Large animal model of left ventricular aneurysm. *Ann Thorac Surg* 1989;48:838-845
21. Kelley ST, Malekan R, Gorman JH III, Jackson BM, Gorman RC, Suzuki Y, Plappert T, Bogen DK, St. John Sutton MG, Edmunds LH Jr: Restraining infarct expansion preserves left ventricular geometry and function after acute anteroapical infarction. *Circulation* 1999;99:135-142
22. Jugdutt BI: Myocardial salvage by intravenous nitroglycerin in conscious dogs: loss of beneficial effect with marked nitroglycerin-induced hypotension. *Circulation* 1983;68:673-684
23. Jugdutt BI, Khan MI: Effect of prolonged nitrate therapy on left ventricular remodeling after canine acute myocardial infarction. *Circulation* 1994;89:2297-2307
24. Jugdutt BI, Khan MI, Jugdutt SJ, Blinston GE: Impact of left ventricular unloading after late reperfusion of canine

- anterior myocardial infarction on remodeling and function using isosorbide-5-mononitrate. *Circulation* 1995;92:926–934
25. Jugdutt BI, Joljart MJ, Khan MI: Rate of collagen deposition during healing after myocardial infarction in the rat and dog models: mechanistic insights into ventricular remodeling. *Circulation* 1996;94:94–101
 26. Jugdutt BI. Left ventricular rupture threshold during the healing phase after myocardial infarction in the dog. *Can J Physiol Pharmacol* 1987;65:307–316
 27. Jugdutt BI. Effect of nitroglycerin and ibuprofen on left ventricular topography and rupture threshold during healing after myocardial infarction in the dog. *Can J Physiol Pharmacol* 1988;66:385–395
 28. Dell'Italia LJ, Meng QC, Balcells IME, Straeter-Knowlen IM, Hankes GH, Dillon R, Cartee RE, Orr R, Bishop SP, Oparil S, Elton T: Increased ACE and chymase-like activity in cardiac tissue of dogs with chronic mitral regurgitation. *Am J Physiol* 1995;269:H2065–H2073
 29. Sharov VG, Sabbah HN, Shimoyama H, Goussev AV, Lesch M, Goldstein S: Evidence of cardiocyte apoptosis in myocardium of dogs with chronic heart failure. *Am J Pathol* 1996;148:141–149
 30. Goussev A, Sharov VG, Shomoyama H, Tanimura M, Lesch M, Goldstein S, Sabbah HN: Effects of ACE inhibition on cardiomyocyte apoptosis in dogs with heart failure. *Am J Physiol* 1998;275:H626–H631
 31. Jugdutt BI, Michorowski BL, Khan MI: Effect of long-term captopril therapy on left ventricular remodeling and function during healing of canine myocardial infarction. *J Am Coll Cardiol* 1992;19:713–723
 32. McDonald KM, Mock J, D'Aloia A, Parrish T, Hauer K, Francis G, Stillman A, Cohn JN: Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. *Circulation* 1995;91:2043–2048